Phase 2 studies of oral hypoxia-inducible factor prolyl hydroxylase inhibitor FG-4592 for treatment of anemia in China

Nephrology Dialysis Transplantation

Volumn 32, Issue 8, 2017, Pages 1373-1386

  Chen, Nan ^a   Qian, Jiaqi ^b   Chen, Jianghua ^c   Yu, Xueqing ^d   Mei, Changlin ^e   Hao, Chuanming ^f   Jiang, Gengru ^g   Lin, Hongli ^h   Zhang, Xinzhou ⁱ   Zuo, Li ^j   He, Qiang ^k   Fu, Ping ^l   Li, Xuemei ^m   Ni, Dalvin ⁿ   Hemmerich, Stefan ⁿ   Liu, Cameron ⁿ   Szczech, Lynda ⁿ   Besarab, Anatole ⁿ   Neff, Thomas B ⁿ   Peony Yu, Kin Hung ⁿ   Valone, Frank H ⁿ   more..

^a SHANGHAI JIAO TONG UNIVERSITY SCHOOL OF MEDICINE   (China)

^b SHANGHAI JIAO TONG UNIVERSITY SCHOOL OF MEDICINE   (China)

^c ZHEJIANG UNIVERSITY   (China)

^d SUN YAT SEN UNIVERSITY   (China)

^e SECOND MILITARY MEDICAL UNIVERSITY   (China)

^f FUDAN UNIVERSITY   (China)

^g SHANGHAI JIAO TONG UNIVERSITY   (China)

^h DALIAN MEDICAL UNIVERSITY   (China)

ⁱ SHENZHEN PEOPLE'S HOSPITAL   (China)

^j PEKING UNIVERSITY FIRST HOSPITAL   (China)

^k Sichuan Province Hospital   (China)

^l SICHUAN UNIVERSITY   (China)

^m PEKING UNION MEDICAL COLLEGE HOSPITAL   (China)

ⁿ FIBROGEN INC   (United States)

more..

Author keywords

anemia in chronic kidney disease; erythropoiesis; erythropoietin; FG 4592; hypoxia inducible factor

Indexed keywords

CHOLESTEROL; HEMOGLOBIN; HEPCIDIN; IRON; PLACEBO; RECOMBINANT ERYTHROPOIETIN; ROXADUSTAT; TRANSFERRIN; EGLN2 PROTEIN, HUMAN; FG-4592; GLYCINE; HYPOXIA INDUCIBLE FACTOR PROLINE DIOXYGENASE; ISOQUINOLINE DERIVATIVE;

ABDOMINAL DISCOMFORT; ADULT; ANEMIA; ARTICLE; CHRONIC KIDNEY FAILURE; CONTROLLED STUDY; DIARRHEA; DIZZINESS; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG MEGADOSE; DRUG SAFETY; DRUG WITHDRAWAL; FEMALE; HEADACHE; HEMODIALYSIS; HUMAN; HYPERKALEMIA; HYPERTENSION; IRON BINDING CAPACITY; IRON BLOOD LEVEL; LIVER INJURY; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MALE; MUSCLE SPASM; NAUSEA; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RASH; RHINOPHARYNGITIS; SIDE EFFECT; TREATMENT OUTCOME; UPPER RESPIRATORY TRACT INFECTION; VOMITING; ADOLESCENT; AGED; ANALOGS AND DERIVATIVES; ANTAGONISTS AND INHIBITORS; CLINICAL TRIAL; COHORT ANALYSIS; COMPLICATION; MIDDLE AGED; VERY ELDERLY; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANEMIA; COHORT STUDIES; DOUBLE-BLIND METHOD; FEMALE; GLYCINE; HUMANS; HYPOXIA-INDUCIBLE FACTOR-PROLINE DIOXYGENASES; ISOQUINOLINES; MALE; MIDDLE AGED; RENAL DIALYSIS; RENAL INSUFFICIENCY, CHRONIC; YOUNG ADULT;

EID: 85018412680     PISSN: 09310509     EISSN: 14602385     Source Type: Journal    
DOI: 10.1093/ndt/gfx011     Document Type: Article

References (48)

1. US Center for Disease Control. National Chronic Kidney Disease Fact Sheet 2014. http://www.cdc.gov/diabetes/pubs/pdf/kidney-factsheet.pdf (9 July 2016, date last accessed)
2. Zhang L, Wang F, Wang L, et al. Prevalence of chronic kidney disease in China: A cross-sectional survey. Lancet 2012; 379: 815-822
3. Chen N, Wang W, Huang Y, et al. Community-based study on CKD subjects and the associated risk factors. Nephrol Dial Transplant 2009; 24: 2117-2123
4. Collins AJ, Ma JZ, Xia A, et al. Trends in anemia treatment with erythropoietin usage and patient outcomes. Am J Kidney Dis 1998; 32: S133-S141
5. Levin A. The treatment of anemia in chronic kidney disease: Understandings in 2006. Curr Opin Nephrol Hypertens 2007; 16: 267-271
6. Mohanram A, Zhang Z, Shahinfar S, et al. The effect of losartan on hemoglobin concentration and renal outcome in diabetic nephropathy of type 2 diabetes. Kidney Int 2008; 73: 630-636
7. Lawler EV, Bradbury BD, Fonda JR, et al. Transfusion burden among patients with chronic kidney disease and anemia. Clin J Am Soc Nephrol 2010; 5: 667-672
8. Liu L, Yang L, WangM. The clinical stage at which dialysis began in patients with non-diabetic end stage renal disease: A retrospective study. Chin J Blood Purif 2007; 6: 242-246
9. Liu RQ, Chen LFJ, Chen H-X. Retrospective study of baseline rebal function in hemodialysis patients before treatment at hemodialysis centers. Chinese Journal of Integrated Traditional andWestern Nephrology 2013; 14: 326-328
10. Zhang W, Gong Z, Peng X, et al. Clinical characteristics and outcomes of rural patients with ESRD in Guangxi, China: One dialysis center experience. Int Urol Nephrol 2010; 42: 195-204
11. Zhu L-N, Lv WI, Teng J, et al. Association of residual renal function at initiation of dialysis with prognosis in maintenance. Chin J Nephrol 2012; 28: 757-764
12. Li Y, Shi H, Wang WM, et al. Prevalence, awareness, and treatment of anemia in Chinese patients with nondialysis chronic kidney disease: First multicenter, cross-sectional study.Medicine (Baltimore) 2016; 95: E3872
13. United States Renal Data System. Annual Data Report: Atlas of End-Stage Renal Disease in the United States. Bethesda, MD: National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases, 2013
14. Beusterien KM, Nissenson AR, Port FK, et al. The effects of recombinant human erythropoietin on functional health and well-being in chronic dialysis patients. J Am Soc Nephrol 1996; 7: 763-773
15. Besarab A, BoltonWK, Browne JK, et al. The effects of normal as compared with low hematocrit values in patients with cardiac disease who are receiving hemodialysis and epoetin. N Engl JMed 1998; 339: 584-590
16. Drueke TB, Locatelli F, Clyne N, et al. Normalization of hemoglobin level in patients with chronic kidney disease and anemia. N Engl J Med 2006; 355: 2071-2084
17. Pfeffer MA, Burdmann EA, Chen CY, et al. Baseline characteristics in the Trial to Reduce Cardiovascular Events with Aranesp Therapy (TREAT). Am J Kidney Dis 2009; 54: 59-69
18. Singh AK, Szczech L, Tang KL, et al. Correction of anemia with epoetin alfa in chronic kidney disease. N Engl JMed 2006; 355: 2085-2098
19. Besarab A, Frinak S, Yee J.What is so bad about a hemoglobin level of 12 to 13 g/dL for chronic kidney disease patients anyway Adv Chronic Kidney Dis 2009; 16: 131-142
20. Fishbane S. Anemia and cardiovascular risk in the patient with kidney disease. Heart Fail Clin 2008; 4: 401-410
21. Szczech LA, Barnhart HX, Inrig JK, et al. Secondary analysis of the CHOIR trial epoetin-alpha dose and achieved hemoglobin outcomes. Kidney Int 2008; 74: 791-798
22. Unger EF. FDA Perspectives on ESAs for Anemia of Chronic Renal Failure: Hemoglobin Target and Dose Optimization. Joint Meeting of the Cardiovascular and Renal Drugs Advisory Committee and the Drug Safety and Risk Management Advisory Committee (11 September 2007). http://www.fda.gov/ohrms/dockets/ac/07/slides/2007-4315s1-10-FDA-Unger-files/frame.htm (23 September 2016, date last accessed)
23. Zhang Y, Thamer M, Stefanik K, et al. Epoetin requirements predict mortality in hemodialysis patients. Am J Kidney Dis 2004; 44: 866-876
24. Radtke HW, Claussner A, Erbes PM, et al. Serum erythropoietin concentration in chronic renal failure: Relationship to degree of anemia and excretory renal function. Blood 1979; 54: 877-884
25. Erslev AJ. Erythropoietin. NEngl J Med 1991; 324: 1339-1344
26. Babitt JL, Lin HY. Mechanisms of anemia in CKD. J Am Soc Nephrol 2012; 23: 1631-1634
27. BernhardtWM, WiesenerMS, Scigalla P, et al. Inhibition of prolyl hydroxylases increases erythropoietin production in ESRD. J Am Soc Nephrol 2010; 21: 2151-2156
28. Provenzano R, Besarab A, Wright S, et al. Roxadustat (FG-4592) versus epoetin alfa for anemia in patients receiving maintenance hemodialysis: A phase 2, randomized, 6-to 19-week, open-label, active-comparator, dose-ranging, safety and exploratory efficacy study. Am J Kidney Dis 2016; 67: 912-924
29. Semenza GL, Agani F, Booth G, et al. Structural and functional analysis of hypoxia-inducible factor 1. Kidney Int 1997; 51: 553-555
30. Peyssonnaux C, Nizet V, Johnson RS. Role of the hypoxia inducible factors HIF in iron metabolism. Cell Cycle 2008; 7: 28-32
31. Nangaku M, Kojima I, Tanaka T, et al. Novel drugs and the response to hypoxia: HIF stabilizers and prolyl hydroxylase. Recent Patents Cardiovasc Drug Discov 2006; 1: 129-139
32. Besarab A, Provenzano R, Hertel J, et al. Randomized placebo-controlled dose-ranging and pharmacodynamics study of roxadustat (FG-4592) to treat anemia in nondialysis-dependent chronic kidney disease (NDD-CKD) patients. Nephrol Dial Transplant 2015; 30: 1665-1673
33. Provenzano R, Besarab A, Sun CH, et al. Oral hypoxia-inducible factor prolyl hydroxylase inhibitor Roxadustat (FG-4592) for the treatment of anemia in patients with CKD. Clin J Am Soc Nephrol 2016; 11: 982-991
34. Levey AS, Bosch JP, Lewis JB, et al. A more accurate method to estimate glomerular filtration rate from serum creatinine: A new prediction equation. Modification of Diet in Renal Disease Study Group. Ann Intern Med 1999; 130: 461-470
35. Eschbach JW, Abdulhadi MH, Browne JK, et al. Recombinant human erythropoietin in anemic patients with end-stage renal disease. Results of a phase III multicenter clinical trial. Ann InternMed 1989; 111: 992-1000
36. Karaboyas A, Zee J, Morgenstern H, et al. Understanding the recent increase in ferritin levels in United States dialysis patients: Potential impact of changes in intravenous iron and erythropoiesis-stimulating agent dosing. Clin J AmSoc Nephrol 2015; 10: 1814-1821
37. KDIGO Anemia Work Group. KDIGO clinical practice guideline for anemia in chronic kidney disease. Kidney Int Suppl 2012; 2: 279-335
38. Provenzano R, Goodkin D, Klaus S, et al. Evaluation of FG-4592, a novel oral hypoxia-inducible factor prolyl hydroxylase inhibitor, to treat anemia in hemodialysis patients. Am J Kidney Dis 2011; 57: B80
39. Macdougall IC, Tucker B, Thompson J, et al. A randomized controlled study of iron supplementation in patients treated with erythropoietin. Kidney Int 1996; 50: 1694-1699
40. Besarab A, Chernyavskaya E, Motylev I, et al. Roxadustat (FG-4592): Correction of anemia in incident dialysis patients. J AmSocNephrol 2016; 27: 1225-1233
41. Bailie GR, Larkina M, Goodkin DA, et al. Data from the dialysis outcomes and practice patterns study validate an association between high intravenous iron doses and mortality. Kidney Int 2015; 87: 162-168
42. Ferezou J, Richalet JP, Coste T, et al. Changes in plasma lipids and lipoprotein cholesterol during a high altitude mountaineering expedition (4800 m). Eur J Appl Physiol Occup Physiol 1988; 57: 740-745
43. Besarab A, Leong R, FrancoMet al. FG-4592, a novel oral hypoxia-nducible factor stabilizer, raises hemoglobin in diabetic subjects with anemia of chronic kidney disease. Abstract # 5847 from the Scientific Sessions of the American Diabetes Association (21-25 June 2013), Chicago, IL
44. Nguyen AD, McDonald JG, Bruick RK, et al. Hypoxia stimulates degradation of 3-hydroxy-3-methylglutaryl-coenzyme A reductase through accumulation of lanosterol and hypoxia-inducible factor-mediated induction of insigs. J BiolChem2007; 282: 27436-27446
45. Baigent C, Landray MJ, Reith C, et al. The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (Study of Heart and Renal Protection): A randomised placebo-controlled trial. Lancet 2011; 377: 2181-2192
46. Wenger RH, Hoogewijs D. Regulated oxygen sensing by protein hydroxylation in renal erythropoietin-producing cells. Am J Physiol Renal Physiol 2010; 298: F1287-F1296
47. Koch GG, Amara IA, Stokes ME, et al. Categorical data analysis. In: DA Berry (ed). Statistical Methodology in Pharmaceutical Sciences. New York, NY:Marcel Dekker, 1990, 291-475
48. Wenger RH, Hoogewijs D. Koury MJ, et al. Anaemia in kidney disease: Harnessing hypoxia responses for therapy. Nat Rev Nephrol 2015; 11: 394-410